Page 21 - Eceptor News Today

Persistent blocking of NMDAR and burst-type firing by lateral habenula (LHb) neurons may offer a basis for the long-lasting antidepressant effects of ketamine.

In a study published in Scientific Reports, researchers engineer long-lasting GLP-1 receptor agonists by fusing GLP-1 with an HSA-binding protein. These chimeric molecules show promise for the treatment of type 2 diabetes due to their stability, functionality, and high affinity for the GLP-1 receptor and human serum albumin.

The efficacy, tolerability, and safety of various anti-Parkinson's drugs.

Researchers discuss the mechanisms responsible for the sustained antidepressant effects of ketamine by examining ketamine-NMDAR interactions.

Researchers are investigating how the most common type of breast cancer resists hormone therapy, thanks to new funding from Breast Cancer Now.

Researchers discuss the results of a randomized controlled trial to explore the impact of diet on breast cancer recurrence.

Researchers identify a pathophysiological mechanism linking serotonin reduction to the multifaceted etiology of post-acute sequelae of COVID-19.

The histopathologic alteration caused by SARS‑CoV‑2 on mammalian neurological systems.

Patients with multiple myeloma treated with idecabtagene vicleucel, known as "ide-cel," a chimeric antigen receptor (CAR) T-cell therapy, had no difference in overall survival outcomes regardless of race and ethnicity, according to a study published in Blood Advances.

New orally-administered GLP-1 receptor agonists danuglipron and orforglipron show promise in treating type 2 diabetes and obesity, according to a systematic review. While effective in glycemic control and weight reduction, these drugs come with gastrointestinal side effects that may lead to treatment discontinuation.